[BTX] BioTime, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 3.82 Change: 0.06 (1.46%)
Ext. hours: Change: 0 (0%)

chart BTX

Refresh chart

Strongest Trends Summary For BTX

BTX is in the medium-term down -48% below S&P in 7 months. In the long-term down -61% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: BioTime, Inc., a biotechnology company, is engaged in the research and product development in the field of regenerative medicine. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, cGMP-capable human embryonic stem cell lines, and differentiation kits, as well as offers Hextend, a blood plasma volume expander to treat hypovolemia in surgery, emergency trauma treatment, and other applications. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; and stem cell-based therapies for retinal and neurological disorders. It also develops HyStem hydrogels, such as ReG

Fundamental Ratios
Shares Outstanding EPS-0.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 14.18% Sales Growth - Q/Q-32.69% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-55.21% ROE-66.91% ROI-143.23%
Current Ratio3.48 Quick Ratio3.44 Long Term Debt/Equity0.03 Debt Ratio0.14
Gross Margin82.19% Operating Margin-974.95% Net Profit Margin-707.22% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities Cash From Operating Activities-230 K Gross Profit70 K
Net Profit80 K Operating Profit80 K Total Assets700 K Total Current Assets670 K
Total Current Liabilities440 K Total Debt80 K Total Liabilities440 K Total Revenue140 K
Technical Data
High 52 week2.85 Low 52 week0.86 Last close1.2 Last change-3.23%
RSI44.93 Average true range0.09 Beta0.82 Volume263.3 K
Simple moving average 20 days-1.09% Simple moving average 50 days8.67% Simple moving average 200 days-37.49%
Performance Data
Performance Week2.56% Performance Month25.25% Performance Quart-28.99% Performance Half-51.61%
Performance Year-54.37% Performance Year-to-date31.43% Volatility daily10.66% Volatility weekly23.84%
Volatility monthly48.87% Volatility yearly169.28% Relative Volume328.96% Average Volume917.05 K
New High New Low

News

2019-03-18 08:00:00 | BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019

2019-03-14 23:50:58 | Edited Transcript of BTX earnings conference call or presentation 14-Mar-19 8:30pm GMT

2019-03-14 17:02:21 | BioTime: 4Q Earnings Snapshot

2019-03-14 16:05:00 | BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

2019-03-11 08:00:00 | BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company

2019-03-07 08:00:00 | BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019

2019-03-04 08:00:00 | BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics AOPT 2019 on March 10, 2019

2019-02-26 08:00:00 | BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting ARVO 2019

2019-02-22 07:55:00 | Consolidated Research: 2019 Summary Expectations for Walmart, W.R. Grace, BioTime, Genesee & Wyoming, Northrop Grumman, and Versum Materials — Fundamental Analysis, Key Performance Indications

2019-02-14 08:00:00 | BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias

2019-02-05 09:00:00 | Most Intriguing Companies on the New LD Micro Index

2019-01-30 08:00:00 | BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer

2019-01-30 08:00:00 | Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals

2019-01-09 08:00:00 | AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity

2019-01-07 08:00:00 | BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD

2019-01-04 08:00:00 | BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase

2019-01-02 08:00:00 | BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019

2019-01-02 07:00:00 | AgeX Therapeutics to Present at Biotech Showcase 2019

2018-12-23 11:38:33 | BioTime, Inc. BTX: Are Hedge Funds Right About This Stock?

2018-12-04 08:00:00 | BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke

2018-12-03 07:55:00 | New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production

2018-11-29 08:00:00 | BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018

2018-11-29 08:00:00 | AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference

2018-11-29 07:00:00 | AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American

2018-11-28 08:00:00 | BioTime Announces Distribution of AgeX Therapeutics Shares

2018-11-09 16:10:00 | Asterias Biotherapeutics Reports Third Quarter Results

2018-11-08 23:35:22 | Edited Transcript of BTX earnings conference call or presentation 8-Nov-18 1:30pm GMT

2018-11-08 13:49:08 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Asterias Biotherapeutics, Inc. AST on Behalf of Stockholders and Encourages AST Investors to Contact the Firm

2018-11-08 07:53:41 | What Kind Of Shareholder Owns Most BioTime Inc NYSEMKT:BTX Stock?

2018-11-08 07:11:12 | BioTime: 3Q Earnings Snapshot

2018-11-08 06:35:00 | BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company

2018-11-08 06:30:00 | BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-11-06 16:30:00 | BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call

2018-11-05 08:00:00 | BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.

2018-11-01 11:28:03 | Earnings Preview: BioTime BTX Q3 Earnings Expected to Decline

2018-10-30 08:00:00 | BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018

2018-10-29 08:00:00 | BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

2018-10-25 08:00:00 | BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares

2018-10-23 07:45:00 | Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-22 08:00:00 | BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th

2018-09-27 07:00:00 | BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences

2018-09-25 07:00:00 | BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies

2018-09-21 07:00:00 | BioTime Warrants to Expire on October 1, 2018

2018-09-18 07:00:00 | BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer

2018-09-17 01:00:00 | BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders

2018-09-04 09:37:01 | Can The Uptrend Continue for BioTime BTX?

2018-09-04 06:55:00 | BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

2018-08-28 07:00:00 | BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences

2018-08-23 08:25:00 | Research Report Identifies Cloudera, Snap, Social Reality, BioTime, Renewable Energy Group, and Mattel with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-08-16 08:00:00 | AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance